Introduction
Hemolytic uremic syndrome (HUS) is a prototype of thrombotic microan giopathy (TMA) and is characterized by the clinical triad of microangiopa thic hemolytic anemia, thrombocytopenia, and acute kidney injury (AKI) 1) . The atypical form of HUS (aHUS) is distinguished from the typical form by the absence of a prior verotoxinproducing Escherichia coli infection. Notably, aHUS may be classified as a primary condition or may occur secondary to bone marrow transplantation, the use of specific drugs, pneumococcal or viral infections, and autoimmune diseases 1) . Primary aHUS is caused by ab normal activation of the alternative complement pathway, and various kinds of genetic mutations have been reported in patients with aHUS, including mutations in the genes encoding complement factor H (CFH), complement factor I, membrane cofactor protein (MCP/CD46), com plement 3 (C3), complement factor B, and thrombomo dulin, among others 2, 3) . An acquired www.chikd.org form of aHUS that primarily affects children aged 9-13 years is observed in those who present with aHUS in association with antiCFH autoantibodies (antiCFH aHUS) 46) . We report a case of a 13yearold Lao girl with clinical features of aHUS, most likely antiCFHaHUS.
Case report
A 13yearold previously healthy girl reported a weight gain of 3 kg (from 48 kg to 51 kg) over 3 weeks prior to pre sentation with gradually increasing edema. She visited a local hospital in Vientiane, Laos PDR and underwent la boratory testing that showed the following results: hemo globin 6.2 g/dL, platelet count 76,000 cells/mm 3 , serum potassium 6.9 mEq/L, blood urea nitrogen (BUN) 205 mg/ dL, serum creatinine 5.5 mg/dL, serum albumin 2.9 g/dL, and serum cholesterol 289 mg/dL. Urinalysis showed 4+ proteinuria and 4+ blood. She was clinically diagnosed with nephrotic syndrome and treated with oral prednisolone (60 mg/day), enalapril, and kalimate. She also received 20% albumin infusion (100 mL/day for 3 days), transfusion of 1 unit of packed red blood cells, and furosemide infusion (20 mg/day for 2 days). Despite this management, her condi tion did not improve, and she was transferred to Children's Hospital, Vientiane, Laos PDR. Upon admission, she appeared pale and edematous, al though her consciousness was clear. She denied any prece ding diarrheal or infectious diseases. Her family history was unremarkable without any history of renal and hema tological diseases. She denied the use of any herbal medi cine. Her body temperature was normal, her height and weight were higher than the 90 th percentiles, systolic blood pressure varied between 120 and 140 mmHg, and her neu rological status was E4V5M6 (using the Glasgow Coma Scale). Her serum hemoglobin level was 6.7 g/dL, reticulocyte count was 3.3%, and platelet count was 103,000 cells/mm 3 . Serum sodium, potassium, and chloride levels were 134, 7.1, and 102 mEq/L, respectively. Serum uric acid level was 19 mg/dL. BUN and serum creatinine were 178 and 2.73 mg/dL, respectively, and serum albumin level was 3.2 g/dL. Her C3 level was 33 mg/dL (reference range 79-1.52 mg/ dL), and complement 4 level (C4) was 18 mg/dL (reference range 16-38 mg/dL). Urinalysis revealed 4+ proteinuria and 4+ blood, and the spot urine protein to creatinine ratio was 1.47 mg/mg. Antinuclear antibody, antidouble stranded DNA antibody and antismooth muscle antibody were negative. Her antistreptolysin O (ASO) titer was 200 IU/ mL. Direct and indirect Coombs tests showed negative re sults. Hepatitis B and C virus markers were negative. Renal ultrasonography revealed that the kidneys were normal in size.
She was presumptively diagnosed with rapidly progres sive glomerulonephritis (RPGN) secondary to acute post streptococcal glomerulonephritis (APSGN) and treated with intravenous methylprednisolone (30 mg/kg/day) for 3 consecutive days followed by oral prednisolone (60 mg/ day). Her serum creatinine decreased to 1.91 mg/dL; how ever, anemia and thrombocytopenia persisted. On the 7 th day of hospitalization, she developed worsening renal function (BUN and serum creatinine levels were elevated to 143 mg/dL and 5.1 mg/dL, respectively) with gradually worsening oliguria. Peripheral blood smear examination showed abundant helmet cells and a reduced platelet count, suggesting TMA (Fig. 1) . Based on the absence of preceding diarrheal illness, abnormal activation of the alternative complement pathway, and the age of disease onset, aHUS (possibly antiCFHaHUS) was considered the most likely diagnosis. Therefore, a second series of methylprednisolone pulse therapy (30 mg/kg/day for 3 consecutive days) con comitant with fresh frozen plasma (FFP) infusion therapy (10 mL/kg/day for 2 consecutive days) was instituted, which improved her renal function (serum creatinine 1.4 mg/dL), anemia (hemoglobin 9.5 g/dL), thrombocytopenia (349,000 platelets/mm 3 ), proteinuria, and oliguria. However, a few days later, her symptoms again worsened with the develop ment of infectious diarrhea and severe pneumonia. Despite the administration of large doses of antibiotics and repeated FFP infusions, she developed severe respiratory distress with bilateral pleural effusions (requiring mechanical ven tilation), uncontrolled hypertension, and severe thrombo cytopenia with petechiae and purpura. She developed ge neralized seizures and rightsided paralysis on the 40th day of hospitalization. Her parents decided to take her home, and she died at home. The serial laboratory findings of the patient were summarized in Table 1 .
Discussion
The patient's initial clinical presentation including mas sive proteinuria, hematuria and azotemia indicated AKI due to glomerulonephritis. Furthermore, we suspected RPGN because of the rapid deterioration of renal function. This presentation combined with laboratory tests indica ting borderline ASO titers and low C3 but normal C4 serum levels, led to a presumptive diagnosis of APSGN because this is the most common etiology in such patients. How ever, the occurrence of AKI, microangiopathic hemolytic anemia, and thrombocytopenia represented the clinical triad that fulfilled the diagnostic criteria for TMA. Among the various etiologies of TMA, antiCFHaHUS was the most likely condition in this patient, considering the ab sence of preceding diarrheal illness, abnormally activated alternative complement pathway, and her age at disease onset. A partial response to initial treatment with high dose corticosteroids also suggested the diagnosis of anti CFHaHUS. Unfortunately, a kidney biopsy and laboratory tests to confirm the diagnosis were unavailable in our hos pital and also in our country. Following the diagnosis of aHUS (possibly antiCFHaHUS), highdose corticosteroid and plasma infusion therapy improved her general condi tion as well as her laboratory test results, including renal function and hematological profiles. These findings strongly suggested the diagnosis of antiCFHaHUS. However, the patient died of infectious complications.
Approximately 50% of patients with aHUS demonstrate genetic or autoimmune abnormalities causing dysregula tion of the alternative complement pathway 7) . CFH is the most commonly affected gene, and patients with CFH mu tations comprise 20-30% of all patients with aHUS 7) . The presence of antiCFH autoantibodies causes functional deficiency of CFH 46) . AntiCFHaHUS has been reported mainly in children aged 9-13 years, although all age groups including infants and adults may be affected 6) . On the other hand, the onset age of pediatric aHUS in association of ge netic mutations is primarily before the age of 2 years, and onset earlier than 3 months of age is characteristic of CFH and CIF mutationassociated aHUS 8) . The prevalence of antiCFHaHUS shows ethnic differences. However, pre valence in studies reporting exclusively pediatric cases (10-56% of total cases with aHUS) 2,911) is higher than that www.chikd.org in studies reporting both, pediatric and adult cases (5-10 %) 3, 11, 12) . A large cohort study that included patients with antiCFHaHUS 6) reported that abnormal activation of the alternative complement pathway (low serum C3 levels with normal C4 levels) was observed in 58% of the patients at disease onset, as was observed in our patient. Interestingly, patients with antiCFHaHUS commonly present with severe abdominal pain and vomiting (84%) and diarrhea (53%) at disease onset 6) . Owing to these fin dings, antiCFHaHUS is often indistinguishable from the typical form of HUS. Additionally, extrarenal complica tions during the acute phase are more common than those in patients with aHUS in association with genetic muta tions. The common complications are seizures in 23.5%, pancreatitis in 23.1%, and hepatitis in 50% of patients 6) . Our patient did not show any such extrarenal complications during the acute phase, but she developed seizures with hemiparesis later during the disease course.
The mainstay of treatment for antiCFHaHUS during the acute phase is early initiation of plasma exchange to remove the circulating autoantibodies and administration of corticosteroids and immunosuppressants (cyclopho sphamide or rituximab) to reduce or prevent continued autoantibody production. This therapy is followed by main tenance immunosuppressant therapy (mycophenolate mofetil) 13) . Because plasmapheresis was unavailable in our hospital, the patient received repeated plasma transfusion instead. Although plasma infusion does not remove the circulating autoantibodies antibody, it can, at least partially, correct abnormal plasma complement profiles, which re sulted from abnormal activation of the complement alter native pathway. Therefore, plasma infusion can be used as an alternative treatment for plasmapheresis when plasma exchange is unavailable or when vascular access for plas mapheresis is difficult. However, plasma infusion may result in or aggravate volume overload.
A few case reports have described that eculizumab is effective in these patients 14, 15) ; however, further studies are necessary to conclusively establish the role of eculizumab in patients with antiCFHaHUS. The longterm prognosis of antiCFHaHUS is similar to that of other forms of aHUS. Patients show a high frequency of relapse (59%), chronic kidney disease (39%), endstage renal disease (27 %), and death (9.5%)6).
In conclusion, this is the first case report that describes aHUS in Laos. A 13yearold girl presented with microan giopathic hemolytic anemia, thrombocytopenia, and AKI without preceding diarrheal illness. Low serum levels of C3 but normal levels of C4 indicated abnormal activation of the alternative complement pathway. Treatment with plasma infusion and highdose corticosteroid therapy, which are the best possible treatment options available in Laos, led to improvement in her renal function and hema tological profile. However, she died of infectious complica tions. Clinicians should suspect aHUS and evaluate further in patients presenting with azotemia, anemia and throm bocytopenia without preceding diarrheal disease, although it is very rare.
